Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes-Reference-Cited by-同舟云学术

Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes

Published:2023-04 Issue: Volume:160 Page:114365
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Meléndez Giselle C.,Kavanagh Kylie,Gharraee Nazli^ORCID,Lacy Jessica L.,Goslen Kevin H.,Block Masha,Whitfield Jordyn,Widiapradja Alexander,Levick Scott P.

Funder

National Institutes of Health

Wake Forest School of Medicine

Errett Fisher Foundation

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference55 articles.

1. ACCF/AHA guideline for the management of heart failure: a report of the American College of cardiology foundation/american heart association task force on practice guidelines;Yancy;J. Am. Coll. Cardiol.,2013

2. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

3. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity;Jia;Circ. Res,2018

4. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities;Russo;J. Mol. Cell. Cardiol.,2016

5. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy;Marwick;J. Am. Coll. Cardiol.,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potentiation of Collagen Deposition by the Combination of Substance P with Transforming Growth Factor Beta in Rat Skin Fibroblasts;International Journal of Molecular Sciences;2024-02-03

2. Salvianolic acid B ameliorates myocardial fibrosis in diabetic cardiomyopathy by deubiquitinating Smad7;Chinese Medicine;2023-12-10

3. Transglutaminases in fibrosis—overview and recent advances;American Journal of Physiology-Cell Physiology;2023-10-01